
    
      This is a single center, open-label, single arm study in patients who have solid or
      micropapillary adenocarcinoma with pathologic stage I and primary tumor no more than 4 cm.
      Patients will be treated with pembrolizumab 200 mg every 3 weeks till 1 year or disease
      recurrence or intolerable toxicity.
    
  